In a report released today, Ritu Baral from TD Cowen maintained a Buy rating on Alto Neuroscience, Inc. (ANRO – Research Report). The company’s shares opened today at $14.00.
Baral covers the Healthcare sector, focusing on stocks such as Neurogene, Milestone Pharmaceuticals, and COMPASS Pathways. According to TipRanks, Baral has an average return of 6.5% and a 43.18% success rate on recommended stocks.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Alto Neuroscience, Inc. with a $32.33 average price target.
The company has a one-year high of $24.00 and a one-year low of $12.78. Currently, Alto Neuroscience, Inc. has an average volume of 177.1K.
Based on the recent corporate insider activity of 14 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of ANRO in relation to earlier this year.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Alto Neuroscience, Inc. (ANRO) Company Description:
Alto Neuroscience is a clinical-stage biopharmaceutical company with a mission to redefine neuropsychiatric care by leveraging neurobiology to develop personalized and highly effective treatment options. Through our AI-enabled biomarker platform, we combine rich sources of information on patients¿ brain activity and behavior to better identify which patients are more likely to respond to our novel product candidates.
